Somerset, N.J. – April 30, 2014 - Dr. Michael Sadick, Senior Manager, Large Molecular Analysis and Characterization, at Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, is to present at the IBC Life Sciences Conference on Biological Assays, which takes place from May 5th to 7th at the DoubleTree by Hilton Berkeley Marina Hotel, Berkeley, California. His presentation, “What are We Monitoring to Maintain our Potency Assays?”, takes place on Tuesday, May 6th at 4.30 p.m., and will discuss the need to track key indicators when performing a potency assay to determine whether the assay is accurate, or indicative of a biological component going bad.
Dr. Sadick has over fifteen years of experience within the industry having worked in the research faculty at UCSF Medical Centre before joining Genentech as a Senior Scientist in the Bioassay Group supporting Pharmaceutical Science efforts (Phases I - III) and latterly Eli Lilly and Company. He joined Catalent in 2012, as Senior Manager of Biopharmaceutical Characterization Services where he manages the team responsible for transfer, development, validation, and performance of bioassays and the development, validation, and performance of molecular biological approaches, including qPCR and cell engineering. In addition, his group is responsible for transfer, development, validation, and performance of electro-separation techniques, including slab-gel electrophoresis and capillary electrophoresis. Dr. Sadick received his Bachelor’s Degree in Biology from Johns Hopkins University and his Master’s Degree and Ph.D. in Immunology from the University of Washington.
Catalent Pharma Solutions offers integrated biologic solutions including advanced cell line and antibody drug conjugation technologies, clinical manufacturing, clinical trial supply and aseptic fill/finish. Alongside this, a broad spectrum of analytical testing services is available to innovators of novel or biosimilar drugs.
Catalent Pharma Solutions is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,500 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and in fiscal 2013 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com